Western University

Scholarship@Western
Medical Biophysics Publications

Medical Biophysics Department

11-8-2019

Synergistic toxicity in an in vivo model of neurodegeneration
through the co-expression of human TDP-43M337V and tauT175D
protein
Alexander J. Moszczynski
Robarts Research Institute

Madeline Harvey
Robarts Research Institute

Niveen Fulcher
Schulich School of Medicine & Dentistry

Cleusa de Oliveira
Schulich School of Medicine & Dentistry

Patrick McCunn
Schulich School of Medicine & Dentistry

See next page for additional authors

Follow this and additional works at: https://ir.lib.uwo.ca/biophysicspub
Part of the Medical Biophysics Commons

Citation of this paper:
Moszczynski, A.J., Harvey, M., Fulcher, N. et al. Synergistic toxicity in an in vivo model of
neurodegeneration through the co-expression of human TDP-43M337V and tauT175D protein. acta
neuropathol commun 7, 170 (2019). https://doi.org/10.1186/s40478-019-0816-1

Authors
Alexander J. Moszczynski, Madeline Harvey, Niveen Fulcher, Cleusa de Oliveira, Patrick McCunn, Neil
Donison, Robert Bartha, Susanne Schmid, Michael J. Strong, and Kathryn Volkening

This article is available at Scholarship@Western: https://ir.lib.uwo.ca/biophysicspub/392

Moszczynski et al. Acta Neuropathologica Communications
https://doi.org/10.1186/s40478-019-0816-1

(2019) 7:170

RESEARCH

Open Access

Synergistic toxicity in an in vivo model of
neurodegeneration through the coexpression of human TDP-43M337V and
tauT175D protein
Alexander J. Moszczynski1,2, Madeline Harvey1, Niveen Fulcher2, Cleusa de Oliveira3, Patrick McCunn4,5,
Neil Donison1,2, Robert Bartha4,5, Susanne Schmid2,3, Michael J. Strong1,6* and Kathryn Volkening1,6

Abstract
Although it has been suggested that the co-expression of multiple pathological proteins associated with neurodegeneration
may act synergistically to induce more widespread neuropathology, experimental evidence of this is sparse. We
have previously shown that the expression of Thr175Asp-tau (tauT175D) using somatic gene transfer with a stereotaxicallyinjected recombinant adeno-associated virus (rAAV9) vector induces tau pathology in rat hippocampus. In this study, we
have examined whether the co-expression of human tauT175D with mutant human TDP-43 (TDP-43M337V) will
act synergistically. Transgenic female Sprague-Dawley rats that inducibly express mutant human TDP-43M337V
using the choline acetyltransferase (ChAT) tetracycline response element (TRE) driver with activity modulating
tetracycline-controlled transactivator (tTA) were utilized in these studies. Adult rats were injected with GFPtagged tau protein constructs in a rAAV9 vector through bilateral stereotaxic injection into the hippocampus.
Injected tau constructs were: wild-type GFP-tagged 2N4R human tau (tauWT; n = 8), GFP-tagged tauT175D 2N4R
human tau (tauT175D, pseudophosphorylated, toxic variant, n = 8), and GFP (control, n = 8). Six months postinjection, mutant TDP-43M337V expression was induced for 30 days. Behaviour testing identified motor deficits
within 3 weeks after TDP-43 expression irrespective of tau expression, though social behaviour and sensorimotor gating
remained unchanged. Increased tau pathology was observed in the hippocampus of both tauWT and tauT175D
expressing rats and tauT175D pathology was increased in the presence of cholinergic neuronal expression of
human TDP-43M337V. These data indicate that co-expression of pathological TDP-43 and tau protein exacerbate
the pathology associated with either individual protein.
Keywords: Microtubule associated protein tau, TDP-43, Comorbid pathologies, Amyotrophic lateral sclerosis
with cognitive impairment, Neurodegeneration, Neuronal cytoplasmic inclusions

Introduction
Amyotrophic lateral sclerosis (ALS) is characterized by
progressive death of upper and lower motor neurons
with death on average 3–5 years after diagnosis [8]. Upwards of 50% of patients are also affected by the presence of cognitive impairment in the form of a florid
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frontotemporal dementia, or milder changes in cognition
and behaviour known as frontotemporal spectrum disorder (ALS-FTSD) [31]. Neurodegenerative diseases,
including ALS and the frontotemporal dementias, are
characterized by the presence of neuropathological
protein inclusions (proteinopathy). The framework of
understanding neurodegenerative disease as specific
“-opathies” has led to the study of individual proteins
mainly in isolation. While it is of critical importance to
understand the mechanisms of toxicity of any diseaserelated protein individually, animal models expressing
these single proteins may be inadequate representations
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of true disease processes as they do not account for the
presence of comorbid pathologies. These models constitutively expressed toxic proteins throughout the central
nervous system and may have been expressing individual
toxic constructs to such a high degree that any subtle effects of the combined expression may have been missed.
The concept of “synergistic interactions” between multiple
toxic proteins has been suggested previously [4] and cooperative activity of proteins likely have profound effects
on the disease state that are, to date, vastly unexplored.
Two of the most frequently observed proteins that
comprise pathological inclusions in a broad range of
neurodegenerative diseases are TAR-DNA binding protein of 43 kDa (TDP-43) and microtubule associated
protein tau (tau). Importantly, TDP-43 is present in
motor neuron pathology in nearly all cases of ALS [17],
and tau protein pathology has been demonstrated in hippocampal and anterior cingulate brain tissues in the vast
majority of cases of ALS with cognitive impairment
(ALSci) [32, 37]. In the context of ALSci, while there is
evidence that both TDP-43 and tau protein expression
are upregulated, they generally do not co-localize within
the same cell populations [37]. Beyond ALSci, the coexistence of TDP-43 and tau pathology has been described
in the form of concomitant argyrophilic grain disease in
ALS [30], Alzheimer’s disease and dementia with Lewy
bodies [12].
In this study, we have utilized a rat model of ALSci to
investigate the impact of pathological TDP-43 expression on hippocampal tau pathology. We hypothesize that
the co-expression of toxic variants of tau and TDP-43 in
distinct neuronal populations will result in increased tau
pathology and a deterioration of motor function.

Materials and methods
All experimental protocols were approved by the University of Western Ontario Animal Care Committee
(AUP #2013–008 and AUP #2017–108) in accordance
with the policies established in the guide to Care and
Use of Experimental Animals prepared by the Canadian
Council on Animal Care.
Animals

All rats were provided ad libitum food and water, and
were kept on a 12 h:12 h light:dark cycle. Wild-type
Sprague-Dawley (SD) rats were acquired from Charles
River Canada. ChAT-tTA and TRE-TDP-43M337V breeding adult rats were purchased from the Rat Resource
and Research Center (Columbia MO, USA) [14, 41]. The
ChAT-tTA line carries the choline acetyltransferase
(ChAT) promoter paired with activity modulating
tetracycline-controlled transactivator (tTA). The TRETDP-43M337V line carries the human TDP-43M337V gene
paired with a tTA-dependent tetracycline response
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element (TRE) driver. Without the presence of the tTA
modulator, the TDP-43M337V gene cannot be expressed
in this model. When these two lines are crossed, the
tTA promoter system activates the TRE-TDP-43M337V
transgene, producing an expression pattern that is indistinguishable from constitutive transgene expression [42].
This promoter is silenced by exposure to tetracycline or
its derivative doxycycline (DOX; Additional file 1: Figure
S1). Therefore, by pairing the tTA and ChAT promoters,
constitutive cholinergic neuronal expression of human
TDP-43M337V is accomplished. Expression was silenced
by the addition of 50 μg/mL DOX in drinking water
(from the time of mating to prevent in utero embryonic
death) which was replenished every 48 h. To express
TDP-43M337V in adult rats, the DOX concentration was
reduced by 50% to 25 μg/mL in the drinking water. This
reduction was selected in favour of full withdrawal to extend the timeline of expression to avoid the rapid onset
of motor dysfunction that has been previously described
in these animals [14]. This model was selected for the
specificity of cholinergic neuronal expression, which is
absent in the hippocampus, but present in lower motor
neurons and cortical neurons [2, 5]. After DOX reduction these rats exhibit the loss of motor neurons and a
motor phenotype consistent with that seen in human
ALS. Genotyping was confirmed by PCR to detect both
ChAT and TDP-43. Expression was confirmed by RTPCR of RNA from animals as previously described [22]
and copy number analyses performed to ensure that
experimental animals had similar transgene loads [22].
Due to the fact that the lines had to be carried as hemizygous lines, and only females were used in these studies,
only 12.5% of the resulting offspring from the crosses were
experimental animals.

Surgical procedure and somatic gene transfer

Somatic gene transfer technique was used to express a
recombinant adeno-associated virus (rAAV9) vector,
allowing for the specific expression of human tau constructs in the hippocampus [22, 25]. We selected the
toxic pseudophosphorylated tau variant human 2N4R
tau with amino acid Thr175 mutated to Asp to mimic
phosphorylation (tauT175D) based on our previous studies in which we demonstrated the toxicity of this ALSci
associated tau variant in cell culture and rodent models
[9, 21, 22, 37]. The constructs were designed to produce
an N-terminus GFP-fused tau protein, which was then
packaged into rAAV9 virus and injected into the hippocampus of the rats as previously described [22, 25].
Expressed constructs were as follows: GFP-tagged wildtype human 2N4R tau (tauWT, n = 6), GFP-tagged tauT175D
protein (pseudophosphorylated construct; tauT175D; n = 6),
and GFP without tau (GFP; n = 6). Vectors, and rAAV9
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viruses were produced by Vector Biolabs (Philadelphia
PA) and have been reported previously [19, 22].
At 3 months of age, female ChAT-tTA/TRE-TDP43M337V and wild-type SD rats were inoculated with
GFP-tagged tau protein construct-bearing rAAV9 vector
through bilateral stereotaxic injection into the hippocampi as previously described [22]. Briefly, animals were
anesthetized with isoflurane and head-fixed in a stereotaxic frame with blunt-ended ear bars and a snout mask.
After a midline incision in the scalp, four burr holes
were drilled into the skull and rAAV9 vectors were
injected bilaterally at two sites per hippocampus at the
following coordinates (± Bregma): A/P: − 5.5 mm, M/L:
±4.6 mm with D/V: − 3.2 mm, and M/L: ±6.0 with D/V:
− 6.0 mm. 3 μl per site was injected over a time of 5 min/
injection. The vector volume was adopted from previously reported studies utilizing adenoviral vectors to
express tau protein in the hippocampus [22, 25]. Postsurgery, rats were individually housed for 1 week before
being returned to paired housing.

Behavioural testing and analyses

As protein expression changed upon prolonged DOX
reduction, ChAT-tTA/TRE-TDP-43M337V (n = 18) and
TRE-TDP-43M337V (TDP-43 control; n = 6) underwent a
battery of behavioural paradigms where phenotypic
changes between groups were examined. All behavioural
testing took place during the light phase (between 7:00
and 19:00 h) and included: open-field test (OFT), prepulse inhibition (PPI) of the acoustic startle response
(ASR), sociability behaviour, and CatWalk tests. Animals
were handled three to four times prior to commencement of behavioural testing. OFT, PPI and sociability
behaviours were assessed prior to 50% DOX reduction
(baseline) to determine baseline measures, followed by
behavioural testing two and 4 weeks post-DOX reduction. CatWalk testing was also analyzed prior to the
DOX reduction, and then at 12 additional time points
over the course of the 4 weeks.

Open-field testing

OFT was used to determine exploratory locomotor behaviour as cumulative distance traveled and to provide a
measure of anxiety-like (thigmotaxis) behaviour. Animals were placed in a square field of 45.7 cm × 45.7 cm
dimension and allowed to freely explore for 20 min while
the animal head location was monitored by an overhead
camera. Data was collected using ANYMAZE software
(V4.99, Stoelting, Wood Dale, IL, USA). The total distance traveled as well as the time spent in the center vs.
periphery of the box was analyzed across the 20 min
testing block.
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Prepulse inhibition of the acoustic startle response

The acoustic startle response (ASR) was used to measure
prepulse inhibition (PPI) which is a behavioural quantification of sensorimotor gating shown to be disrupted in
many neurological diseases [28, 33]. PPI reflects an
attenuation of the startle response following a loud startling stimulus when it is preceded by a low-intensity
stimulus (prepulse) by typically ~ 30-100 ms [16]. PPI is
largely assumed to be mediated by mesopontine cholinergic projections that inhibit the startle pathway at the
level of the pons, but has been suggested to be modulated by the hippocampus, with the CA1 and dentate
gyrus having greatest involvement.
To measure the ASR, as described in Valsamis and
Schmid [34], rats were acclimatized to sound-proof startle boxes (Med Associates, VT, USA) with a constant
background noise of 65 dB over 3 days for 5 min periods.
Input/output function was measured and experimental
testing comprised of three blocks: I) Acclimation period
for 5 min; II) 20 startle-alone stimuli of 20 ms duration
and 105 dB intensity; Block III) 50 pseudorandomized
trials of the same startle stimuli paired with or without a
preceding prepulse stimulus of 4 ms duration at either
75 or 85 dB intensity with 2 different inter stimulus
interval (ISI) of 30 or 100 ms (total of 10 trials/condition). Inter-trial interval was variable between 15 and 25
s. Peak to peak maximum startle magnitude was measured and PPI was expressed as amount of inhibition in
percentage of baseline startle: %PPI = [1 - (startle magnitude with prepulse/baseline startle without prepulse)] ×
100.
Sociability and social recognition testing

Socialization was evaluated due to previous observations
of preferential tau expression in this model in the CA2
region of the hippocampus [22]. This expression pattern
would not lead to changes in traditional behavioural
testing such as the Morris water maze which relies on
performant pathway plasticity and not hippocampal
CA2. Social memory has been shown to be impaired
when this region is pathologically malfunctioning [13].
To test the changes in CA2 function due to pathological
tau protein expression, we conducted a three-chamber
sociability test, similar to that described by others [6].
In brief, the test apparatus was a rectangular Plexiglas
box (40 cm length × 20 cm width × 20 cm height), divided
into 3 areas of equal width and separated by perforated
Plexiglas. Rats were placed in the middle chamber for 5
min of habituation, after which a familiar animal (littermate) was placed into one of the outer chambers. Test
animal was then allowed to investigate both outer chambers and animal activity was recorded using ANYMAZE
software (V4.99, Stoelting, Wood Dale, IL, USA) and
scored over a 5 min test in which the animal sniffed each
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compartment (nose within 2 cm of the divider). Animals
expressing normal sociability are expected to spend a
greater amount of time sniffing the chamber containing
the littermate compared to the empty compartment. Behavioural performance was expressed using sociability
scores (difference between times spent in stranger vs.
empty compartments).
To assess animals for preference for social novelty, an
unfamiliar female rat (stranger) was placed in one of the
side chambers while a familiar cage mate was placed in
the other and test subject was allowed to explore for an
additional 5 min. Time spent in each chamber were recorded and a social preference score (difference between
time spent in the stranger vs. familiar rat chamber) was
calculated for each rat. An animal expressing a normal
preference for social recognition is expected to spend
more time sniffing the chamber containing the novel
stranger.
CatWalk testing

All gait assessment was conducted using a CatWalk XT
gait analysis system (Noldus Toronto, Canada). Subjects
were tested once prior to DOX reduction, followed by
testing 3 days/week post-DOX reduction, with each test
consisting of 3 consecutive runs/day for 4 weeks. The
average of the runs for each week was taken for the calculation of each variable analyzed. Metrics assessed included: body speed and hind paw measures of swing,
swing speed, stand, initial contact, and stride length
(based on [35]).
Neuroimaging

Neurite Orientation Dispersion and Density Imaging
(NODDI) imaging (dMRI) modality was used for imaging the rats used in this study [20, 39, 40]. Images
were acquired at the Centre for Functional and Metabolic
Mapping on an Agilent 9.4 Tesla small animal magnetic
resonance imaging (MRI) scanner (Santa Clara, CA).
Images were acquired using a spin-echo, echo-planarimaging (EPI) acquisition pulse sequence (4 shots, 2 averages, slice thickness = 500 m, FOV 40x40mm, matrix size
160 × 160, in-plane resolution = 250 × 250 m, TE = 25 ms,
TR = 5.0 s) as previously described [20]. A two-shell diffusion sampling scheme was used consisting of 72 b-value =
2000s/mm2 directions (gradient strength (G) = 339.1mT/
m, time between the start of the first and second diffusion
pulse (Δ =14.44 ms, the duration of a single gradient pulse
(δ) = 4.32 ms, TE = 25 ms and TR = 5.0 s) and 36 bvalue = 1000s/mm2 directions (G = 169.6mT/m, Δ = 14.44
ms, δ = 4.32 ms, TE = 25 ms and TR = 5.0 s). Fifteen b = 0
s/mm2 were interspersed throughout the imaging sequence. This imaging sequence has been shown to produce reliable NODDI metrics [20]. Scans were performed
after doxycycline reduction when a disease phenotype
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emerged. The total imaging time was 83 min. Images were
pre-processed using fMRI Software Library (FSL, v.5.0.10,
Oxford, UK). The NODDI Matlab toolbox (available from
the UCL Microstructure Imaging Group) was then used
to produce maps of ODI, NDI, and IsoVF.
Immunohistochemistry

After 30 days of doxycycline reduction, or at end stage
as defined in animal use protocols (paralysis or loss of
10% of body mass), rats were intraperitoneally injected
with a lethal dose of Euthanyl and trans-cardiacally perfused with heparinized saline (10 units heparin/mL, 0.9%
sodium chloride) followed by perfusion fixation with 4%
formaldehyde (pH 7.4). Brains were removed and postfixed in 4% formaldehyde for 24 h before cutting into
sections and embedding in paraffin wax. Tissue was then
serially sectioned at 4–6 μm and mounted to positively
charged microscope slides. With sectioning the brain
prior to embedding each slide captured sections from
five distinct points along the rostrocaudal axis of the
brain per animal.
Immunohistochemistry was conducted to analyze vector expression and the induction of pathology using
rabbit anti-GFP (1:750 titer, Life Technologies, Montreal, Canada), mouse anti-human TDP-43 (1:500 titer,
Proteintech, Rosemont IL, USA) and mouse anti-PHF
tau (AT8; 1:500 titre, ThermoFisher, Montreal, Canada).
The characterization of the extent of microglial activation was conducted using rabbit anti-IBA1 (1:1000 titer,
Wako, Richmond, VA, USA) while astrocytes were
assessed using rabbit anti-GFAP (1:1000 titer, Dako/
Agilent, Santa Clara, CA, USA). Antigen retrieval (10
mM sodium citrate, 0.05% Tween-20 pH 6.0) was conducted for all antibodies using a pressure cooker (2100
Retriever; Aptum Biologics, UK). Endogenous peroxidase
was quenched with 3% hydrogen peroxide (VWR,
Mississauga, Canada). Primary antibody incubation was
performed at 4 °C overnight in blocking buffer (5% BSA,
0.3% Triton-X 100 in 1X PBS). After washing, secondary
antibody (1:200 titer biotinylated IgG) incubation was
performed for 1 h at room temperature in blocking
buffer. Antigen:antibody complex was visualized with
the horseradish peroxidase coupled Vectastain ABC kit
(Vector Laboratories CA, USA) according to the manufacturer’s instructions, followed by substrate development with DAB. Counterstaining was performed using
Harris’ haematoxylin.
To co-stain for axon integrity and myelination, a
modified SMI-31/Luxol fast blue immunohistochemistry
was performed (SMI-31:10,000 titer, BioLegend, San
Diago, USA) as described in Moszczynski et al. (Applied
Immunohistochemistry and Molecular Morphology, in
press). Briefly, Luxol fast blue staining was performed
after SMI-31 IHC by staining in 1% Luxol fast blue
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((Sigma, St. Louis, MO, USA) overnight at 56 °C after
slides were dehydrated post-DAB development. Luxol
fast blue differentiation was performed with 0.05% lithium carbonate and 70% ethanol, followed by dehydration
to xylenes and converslipping.
Co-localization and fluorescence staining

To visualize multiple proteins, TDP-43 was probed with
mouse anti-human TDP-43 (1:500 titer, Proteintech) in
conjunction with rabbit anti-cleaved caspase-3 (Asp175;
clone 5A1E; 1:200 titer, Cell signaling, MA, USA), and
mouse anti-GFP (1:250 titer, Abcam) in conjunction
with rabbit anti-IBA1 (1:1000 titer, Wako) or rabbit
anti-GFAP (1:1000 titer, Dako) primary antibodies overnight at 4 °C and Alexafluor goat anti-mouse 488, donkey anti-rabbit 488, and goat anti-rabbit 555 or donkey
anti-mouse 565 secondary antibodies (all used at 1:200
titer, ThermoFisher) for 1 h at room temperature. Slides
were visualized within 24 h of labeling by confocal imaging on a Zeiss LSM 510 Meta multiphoton confocal
microscope or on an EVOS M7000 imaging system
(ThermoFischer).
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each ventral horn (pathology-bearing motor neurons/total
motor neurons).
Glial activation quantification

After staining with IBA1 or GFAP antibodies, images
were acquired using the 20x objective of an Olympus
BX45 light microscope. A minimum of 5 images were
acquired spanning the entire hippocampus in each of 3
animals per group. Images were then quantified using
ImageJ to generate a numerical percentage of the total
field of view that was stained positive.
Behavioural assessments

Lumbar ventral horns were photographed for 3 rats
from each tau construct expressing group in the TDP-43
expressing ChAT-tTA/TRE-TDP-43M337V line using the
10x objective of an Olympus BX45 light microscope.
After image acquisition, the total number of motor
neurons present (identified by size and the presence of a
prominent nucleus with a typical ‘clock face’ appearance
of the chromatin) in the ventral horn of all lumbar
spinal cord sections was counted by a blinded observer.

IBM SPSS Statistics 23.0 was used for statistical analysis.
Data were expressed as group means ± the standard
error of the mean (SEM). A two-way mixed-design analysis of variance (ANOVA) was used to analyze the
majority of the data, with “time” or “DOX reduction” (3
levels: Before DOX reduction (baseline) vs. 2 weeks after
DOX reduction vs. 4 weeks after DOX reduction) as the
within-subject factor and “genotype” (2 levels: ChATtTA/TRE-TDP-43M337V vs. TRE-TDP-43M337V) or
“tau” (3 levels: GFP vs. tauWT vs. tauT175D) as the
between-subject factors. All behavioural tests, other than
CatWalk, considered the tau injection groups during
analyses. Normality was assessed using a Shapiro-Wilk
test for normality. Homogeneity of variance was assessed
using Levene’s test of homogeneity. Homogeneity of covariance was assessed using Box’s M test. Mauchly’s test
of sphericity was used to test the assumption of sphericity for two-way interactions. If sphericity was violated,
corrections were applied based on the ε value and the
Huynh-Feldt correction. Significance was accepted when
p < 0.05 and outliers were removed by box plot analysis.
We determined the average %PPI for each prepulse type
(dB and ISI combinations) and performed two-way
ANOVA (prepulse type × genotype) and (prepulse type
× tau). Since there were no significant main interaction
on PPI, all PPI ISI and prepulse groups were re-assessed
together and graphed accordingly. For all statistically
significant behavioural results where post hoc analyses
were appropriate, a Student’s t test with Bonferroni corrections was performed.

TDP-43 pathology scoring

Statistical analysis of histopathological data

After staining for human TDP-43, lumbar ventral horns
for 3 rats from each tau construct expressing group on the
ChAT-tTA/TRE-TDP-43M337V line were photographed
using the 10x objective of an Olympus BX45 light microscope. Pathology, defined as the presence of at least one
skein or aggregate, was quantified by a blinded observer
and then the number of pathology-bearing motor neurons
was normalized against total number of motor neurons in

Statistical analyses were conducted using SigmaPlot 10.0
software. A one-way analysis of variance (ANOVA)
was conducted following a Shapiro-Wilk test for normality. Post-hoc Tukey’s test was conducted and a
p ≤ 0.05 was considered significant. For non-normal
data, a Kruskal-Wallace one-way ANOVA on ranks
was conducted followed by a Dunn’s pairwise test for
multiple comparisons.

Quantification and statistical analysis
GFP-tau pathology scoring

Photomicrographs of all GFP-expressing hippocampal
regions were taken for 3 rats in each group (GFP, tauWT,
tauT175D) on both ChAT-tTA/TRE-TDP-43M337V (TDP43 expressing) and wild-type SD background strain using
the 20x objective on an Olympus BX45 light microscope.
Pathology was scored by a trained observer who was
blinded to the expression group. The total number of
pathological events was counted for each field.
Motor neuron counts
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Neuroimaging

A Multivariate Analysis of Variance was performed to
detect any statistically significant differences between
mean ODI, NDI, and IsoVF within the corpus collosum
and hippocampus for each group (GFP, tauWT, and
tauT175D).

Results
ChAT-tTA/TRE-TDP-43M337V animals express human TDP43, develop a marked motor phenotype, and exhibit loss
of motor neurons upon withdrawal of doxycycline

After 30 days of 50% DOX reduction in drinking water,
all rats on the genetic background containing ChATtTA/TRE-TDP-43M337V developed a hind-limb motor
phenotype consistent with that previously described
[41]. Hind limb muscle wasting was observed along with
weakness resulting in an inability to lift the pelvis off the
ground and dragging of the hindlimbs. This was evident
by motor impairment as early as week 3 using the CatWalk gait analyses which demonstrated gait disturbances, including increased latency of hind paw initial
contact, reduced stride length and decreased body speed
(Fig. 1f-h).
In the ChAT-tTA/TRE-TDP-43M337V rats human
TDP-43 expression was observed at 30 days post DOX
reduction in both ventral horn motor neurons (Fig. 1d)
and cortical neurons (Fig. 2d) consistent with previous
studies [14]. Expression of human TDP-43 was not observed in wild-type SD (data not shown), ChAT-tTA
(data not shown), or TRE-TDP-43M337V (without ChATtTA transgenes) groups (see Fig. 1c, and Fig. 2b, e). The
hippocampal expression of human TDP-43 on DOX
withdrawal was variable in the ChAT-tTA /TRE-TDP43M337V rats, varying from extremely weak to strong
expression (compare Fig. 2c, d). When examined for
human TDP-43 expression in spinal motor neurons, all
ChAT-tTA/TRE-TDP-43M337V rats demonstrated TDP43 pathology consistent with that observed in human
ALS including nuclear cytoplasmic inclusions (Fig. 3b),
nuclear depletion of TDP-43 (Fig. 3c), and punctate nuclear TDP-43 deposition (Fig. 3d). Also consistent with
previous results in this model [41], human TDP-43M337V
expression in spinal motor neurons led to the identifiable
presence of pro-apoptotic markers including caspase-3
cleavage and activation in motor neurons (Fig. 3e).
To determine if loss of motor neurons was occurring
as previously described, motor neurons in the ventral
horn of spinal cords were counted across a minimum of
4 separate whole lumbar spinal cord sections in 3 animals per group. Motor neurons were identified by their
large size and classic “clock-face” nuclear staining with
H&E stain. As previously described in this model [14],
mutant ChAT-tTA/TRE-TDP-43M337V rat (TDP-43 expressing) lumbar spinal cord ventral horns contained a
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significantly reduced number of motor neurons (Mean ±
SEM; 4.5 ± 0.27) compared to either ChAT-tTA (8.94 ±
0.87) or TRE-TDP-43M337V (7.3 ± 0.63) non-expressing
parental strains after significant one-way ANOVA on
ranks (p < 0.001) followed by Dunn’s post-hoc analysis
for multiple comparisons (p < 0.05 for each comparison;
Fig. 1e). However, contrary to previous observations
[14], no evidence of degeneration of myelin or axons in
the corticospinal tract was observed. Immunohistochemistry detecting phosphorylated high molecular weight
neurofilament (SMI-31 antibody), coupled with Luxol
fast blue stain, showed preservation of the corticospinal
tracts (Fig. 1a), which may be related to the fact that our
withdrawal scheme for DOX was staged and not abrupt;
however, the reasons behind this are not known at this
point.
Hippocampal injection of tau into rats on the ChAT-tTA/
TRE-TDP-43M337V background

Rats on the ChAT-tTA/TRE-TDP-43M337V genetic background were injected into the hippocampus with AAV9
virus carrying constructs to express GFP alone (control),
GFP fused to tauWT, or GFP fused to tauT175D. The expression of human TDP-43 and tau was then examined.
The tauT175D mutation was used to mimic phosphorylation of the threonine residue at amino acid 175 in
human tau. Phosphorylation at this site is pathological
as has been determined in previous work [1, 9, 21, 22, 24]
and is expressed in humans with ALS and cognitive impairment. The aim of this study was to examine if tau and TDP43, while expressed in different cell populations, may alter
spinal cord or hippocampal pathology when co-expressed.
In spinal motor neurons, all ChAT-tTA/TRE-TDP43M337V rats (with and without hippocampal injection of
any of the GFP/GFP-tau constructs) demonstrated TDP43 pathology consistent with that observed in human
ALS. TDP-43 pathology was quantified by counting all
visible neurons (as assessed by size, position in the ventral horn and nuclear morphology) and assigning a binary response where the presence of an aggregate, skein
or punctate staining (for examples see Fig. 3b, d) was
positive, and the absence of all of these was considered
negative. The simple redistribution of TDP-43 from the
nucleus or a clearing of the nucleus was not considered
pathological for this study (Fig. 3c) to avoid potential
over-estimation of the pathology. The number of cells
displaying aggregates or skeins were normalized against
the total number of motor neurons in each ventral horn
analyzed. One-way ANOVA revealed no significant difference in the extent of pathology between groups (positive motor neurons/total motor neurons; mean ± SEM;
GFP = 0.41 ± 0.09, tauWT = 0.35 ± 0.06, tauT175D = 0.59 ±
0.03, ANOVA p = 0.052). It is noteworthy that a trend
approaching significance (p < 0.1) was observed in the
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Fig. 1 Expression of TDP-43M337V affects motor phenotype. a Immunohistochemical staining for phosphorylated high molecular weight
neurofilament (SMI-31) counterstained with Luxol fast blue shows no apparent loss of myelin in the corticospinal tracts. Inset = higher
magnification of the corticospinal tract showing axonal cross sections (brown) and myelin (green). WM = white matter, GM = grey matter. b GFP
is not expressed in the rat spinal cord when not fused to tau. c Human TDP-43 is not expressed in the TRE-TDP-43M337V rat spinal cord without
the ChAT-tTA transgene. d Human TDP-43 is expressed in cholinergic motor neurons in the spinal cord of ChAT-tTA/TRE-TDP-43M337V rats (brown
staining). All photomicrographs represent rats at 30 days post doxycycline (DOX) reduction. All images were taken at 20x, insets at 40x. e ChATtTA/TRE-TDP-43M337V rats exhibit a reduced number of motor neurons in lumbar spinal cord compared to non-expressing parental transgenic
lines (n = 3/group, 30 days after DOX reduction, mean ± SEM). * = significant Dunn’s post-hoc test for multiple comparisons (p < 0.05) following a
one-way ANOVA (p = 0.01). f Mixed ANOVA found a statistically significant interaction between the genotype (ChAT-tTA/TRE-TDP-43M337V) and
DOX reduction time on hind paw initial contact time in CatWalk XT gait analysis (*p = 0.010; n ≥ 4/group), suggesting that TDP-43 expressing rats
took longer to initially contact the walkway with 50% DOX reduction over time, compared to TDP-43 non-expressing controls. g There was a
statistically significant interaction between the TDP-43M337V and DOX reduction time on hind paw stride length (n ≥ 6/group, p = 0.024). However,
there was no significant main effect of time, suggesting that DOX withdrawn TDP-43 expressing animals generally took smaller strides over time,
compared to TDP-43 non-expressing controls. h There was a statistically significant interaction between the TDP-43M337V and DOX reduction time
on body speed (n ≥ 6/group, p = 0.039) but no main effect of time, suggesting that DOX reduced TDP-43 expressing rats generally slowed down
over time, compared to controls
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Fig. 2 Cerebral expression of human GFP-tagged tau protein constructs and human TDP-43M337V. a Composite image of hippocampus from
ChAT-tTA/TRE-TDP-43 rat expressing tauT175D probed for GFP shows expression of GFP-tagged tauT175D protein throughout the hippocampus
with prominent neuronal and neuritic expression in the CA2 region (brown). This same expression pattern was observed for all three AAV9
injected groups (GFP, GFP-tagged tauWT, and GFP-tagged tauT175D; n = 3 for each group). b TRE-TDP-43M337V hippocampus probed for human
TDP-43 reveals no expression of human TDP-43 confirming that TDP-43 is not expressed without the ChAT-tTA transgene (n = 3). c and d ChATtTA/TRE-TDP-43M337V transgenic rat hippocampus probed for human TDP-43 showed a variety of expression during DOX withdrawal, ranging
from extremely low levels (c) to robust TDP-43 expression (d). e TRE-TDP-43M337V rat cortex probed for human TDP-43 reveals no evidence of
expression (left) while ChAT-tTA/TRE-TDP-43M337V rat cortex shows human TDP-43 expression that is predominantly nuclear (right). All composite
images taken with a 20x objective. Scale bar = 10 μm

tauT175D expressing group for increased motor neuron
TDP-43 pathology (Fig. 3a). It would be of interest to
examine this further in the future to determine if significance is ultimately reached with a larger number of

animals, or by stratifying the animals based on either
time to end stage after doxycycline withdrawal, or by
TDP-43 expression level in the brain after DOX
withdrawal.
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Fig. 3 Spinal cord TDP-43 pathology in ChAT-tTA/TRE-TDP-43M337V rats was detected by immunohistochemistry with anti-TDP-43 antibodies
regardless of hippocampal injected tau construct. a Frequency of pathology-bearing motor neurons normalized against total number of motor
neurons. The presence of spinal TDP-43 pathology approaches significance in the rats expressing tauT175D when compared to GFP expressing rats
(p < 0.1). MN = motor neuron, GFP = GFP only control, tauWT = GFP-tagged tauWT protein construct, tauT175D = GFP-tagged tauT175D protein
construct). This was not significant by one-way ANOVA (p = 0.052). b Photomicrograph showing spinal cord dorsal horn TDP-43 cytosolic
inclusion in a motor neuron. c Photomicrograph of a spinal motor neuron showing depleted nuclear TDP-43 with cytosolic TDP-43 and
surrounding glial cells. d Photomicrograph of spinal motor neurons exhibiting punctate TDP-43 pathology. e Confocal imaging detecting cleaved
caspase-3 (green) in a motor neuron co-expressing human TDP-43 (red) punctate pathology. This was observed in all ChAT-tTA/TRE-TDP-43M337V
rats where TDP-43M337V displayed pathology regardless of hippocampal tau expression (n = 3 for all groups). Scale bar = 20 μm

All AAV9 injected rats expressed GFP specifically in the
hippocampus as previously described [22], with a higher
level of expression noted in the CA2 region extending from
the neuronal cell bodies into the axonal projections
(Fig. 2a). TauWT and tauT175D were expressed as fusion
proteins with N-terminally positions GFP, so that detection
with the anti-GFP antibody would necessarily detect tau.
Caspase-3 cleavage was also examined in ChAT-tTA/
TRE-TDP-43M337V rats. TDP-43 pathology was detected
in all TDP-43 expressing spinal cords, regardless of

which tau (or GFP) was injected, suggesting that the loss
of motor function was due to the loss of motor neurons
through a caspase-dependent cascade leading to cell
death. These observations were consistent with those
previously published [41].
Tau pathology in rats

The constructs to express tau were designed specifically
to be fusions with GFP so that the anti-GFP antibody
could be used to detect tau. GFP-tau immunoreactive
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neuronal cytoplasmic inclusions were observed in the
tauT175D expressing rats in all hippocampal regions
expressing GFP constructs. In the tauT175D infected cells
both fibrils and tangles were easily detected (see Fig. 4a,
b, and c for examples as observed using anti-GFP immunohistochemistry). Consistent with previous results [22]
we observed axonal beading in all groups within GFPimmunoreactive neuritic processes, suggesting that this
was a nonspecific feature of the invasiveness of the surgery itself (Fig. 4b, arrowheads). The frequency of neuropathology was significantly increased in the tauT175D on
wild-type Sprague-Dawley background (Mean ± SEM;
GFP = 1.32 ± 0.28, tauWT = 1.36 ± 0.28, tauT175D = 5.15 ±
1.12; Fig. 4d). This was further elevated in the human
ChAT-tTA/TRE-TDP-43M337V rats where tauT175D pathology was nearly doubled compared to its wild-type SD
background counterpart (GFP expressing ChAT-tTA/
TRE-TDP-43M337V 1.25 ± 0.71, tauWT expressing ChATtTA/TRE-TDP-43M337V 2.34 ± 0.46, tauT175D expressing
ChAT-tTA/TRE-TDP-43M337V 10.08 ± 1.20). The difference in pathology between the two rAAV9 tauT175D
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expressing groups was significant (p = 0.004) while the
presence of tau pathology in the ChAT-tTA/TRE-TDP43M337V group was significantly elevated relative to all
other groups (p < 0.05).
To confirm that the pathology seen with the anti-GFP
antibodies reflects the depostion of human tau protein,
rat hippocampi were probed with the AT8 antibody to
paired helical filaments of tau (Fig. 5). No PHF immunoreactivity was detected in either parental strain (ChATtTA or TRE-TDP-43M337V) or with the expression of
TDP-43 (ChAT-tTA/TRE-TDP-43M337V) with injection
of GFP or GFP-tauWT-rAAV9. PHF tau was robustly detected within neurons in the ChAT-tTA/TRE-TDP43M337V expressing rats that also expressed tauT175D
(Fig. 5). When taken together with the GFP staining described above, it is clear that tau pathology is increased
in the hippocampus of rats expressing TDP-43M337V.
IBA1 staining revealed activated microglia in TauT175D
expressing ChAT-tTA/TRE-TDP-43M337V rat hippocampi that was not observed in ChAT-tTA control rats
(Fig. 6a). An analysis of the percent area coverage of the

Fig. 4 GFP-tau pathology is increased in the presence of TDP-43M337V expression. a GFP-tau positive hippocampal neuron demonstrating a fibril
type inclusion (inset, open arrow). b Photomicrograph of a GFP-tau immunoreactive hippocampal neuron demonstrating a neuronal inclusion
(arrow), axonal swelling (asterisk), and axonal beading (arrowheads). Note that the latter is nonspecific as it was observed across all groups. c GFPtau positive hippocampal neurons showing frequent incidence of pathological inclusions (arrowheads, inset). Scale bars = 20 μm. d Bar graph
showing frequency of pathological inclusions in hippocampus at 20x magnification in each group (GFP = GFP only control, tauWT = GFP-tagged
tauWT, tauT175D = GFP-tagged tauT175D). White bars indicate wild-type Sprague-Dawley rats injected with rAAV9 GFP-tau constructs, green bars
indicate ChAT-tTA/TRE-TDP-43M337V rats expressing human TDP-43M337V injected with rAAV9 GFP-tau constructs (n = 3 animals per group)
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Fig. 5 Hippocampal expression of human GFP-tagged tau protein using AT8 antibody against paired helical filament tau in parental lines and rats
expressing TDP-43 with GFP and/or tau expression. Representative sections from the CA1 region of the hippocampus in rats. Parental lines (ChATtTA and TRE-TDP-43M337V) were not injected with any rAAV9 (top two rows). Rats expressing TDP-43 (ChAT-tTA/TRE-TDP-43M337V were injected
with either rAAV9 encoding GFP alone (GFP), or GFP-fused wildtype tau (tauWT) or GFP-fused tauT175D (tauT175D). Note the staining in the ChATtTA/TRE-TDP-43M337V rats expressing tauT175D (brown, bottom row; n = 3 for each group). Photos in the left column were taken with 40X
objective, right column with oil immersion 100X objective. Scale bar = 20 μm

field (a marker of microglial activation) revealed a higher
overall amount of positive staining in ChAT-tTA/TRETDP-43M337V rats expressing tauT175D relative to the
ChAT-tTA parental control strain (p < 0.05) while GFP
and tauWT groups were not statistically significant from
the parental control strain (Fig. 6b). Fluorescent staining
revealed a phenotype of IBA1 positive microglia in close
proximity to tauT175D positive hippocampal neurons, but
not in other groups (Fig. 6c). Although no significant
differences in GFAP staining were observed between
hippocampal construct expressing groups within ChAT-

tTA/TRE-TDP-43M337V, a trend toward increased GFAPpositive staining was observed in tauT175D hippocampus
(Additional file 2: Figure S2, ANOVA p = 0.072).
Behaviour testing in TDP-43 expressing rats confirm
motor deficits while the addition of tauT175D expression in
these rats leads to subtle behaviour changes

In CatWalk gait analyses, mixed ANOVA detected a
significant interaction between the TDP-43M337V expression and DOX reduction time on hind paw initial
contact time, (F (4, 72) = 3.572, p = 0.010; Fig. 1f), with no
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Fig. 6 Microgliosis is increased in the hippocampus of ChAT-tTA/TRE-TDP-43M337V rats co-expressing pathogenic human tauT175D protein. a
Representative photomicrographs showing IBA1 stained microglia in ChAT-tTA control and tauT175D expressing ChAT-tTA/TRE-TDP-43M337V rat
hippocampus. Insets show an activated microglial cell with enlarged cell body in ChAT-tTA/TRE-TDP-43M337V transgenic rat brain and resting
microglial cell in ChAT-tTA control. Light microscopy low magnification images were taken with 20x objective, insets taken with 100x oil
immersion objective. Scale bar = 50 μm. b Quantification of IBA1 staining across the field of view shows increased coverage (proxy for microglial
activation) in ChAT-tTA/TRE-TDP-43M337V rats with human tauT175D expressed in the hippocampus. All quantification represents either the ChATtTA control group (non-expressing for TDP-43M337V or any GFP construct) or hippocampal GFP-tau expressing groups on ChAT-tTA/TRE-TDP43M337V transgenic background (GFP = green fluorescent protein, tauWT = GFP-tagged tauWT, tauT175D = GFP-tagged tauT175D human tau). *p < 0.05
between indicated groups. c Fluorescence microscopy of the hippocampus of wild type rats (no ChAT/no TDP-43 transgenes; top two rows) and
rats expressing human TDP-43 (bottom two rows) with tauWT (top row and third row) or tauT175D (second and four rows) co-probed with
antibodies to GFP (fusion protein with tau) and IBA1. White arrows indicate IBA1 positive microglial cells in close-proximity to GFP-positive (tau
positive) hippocampal neurons. Three animals were examined for each group and photomicrographs shown are representative for each group

main effect of time, (F (4, 72) = 1.528, p = 0.203) suggesting that ChAT-tTA/TRE-TDP-43M337V animals took
longer to initiate hind paw contact with DOX reduction
over time. No effect of genotype was found, (F (1, 18) =
0.095, p = 0.761). Additionally, there was a statistically
significant interaction between the TDP-43M337V expression and DOX reduction time on hind paw stride length

(distance between successive placements of the same paw),
n ≥ 6/group, (F (4, 100) = 2.940, p = 0.024; Fig. 1g). However,
there was no significant main effect of time, (F (4, 100) =
0.938, p = 0.445) while there was an effect of genotype (F
(1, 25) = 5.616, p = 0.026), suggesting that ChAT-tTA/TRETDP-43M337V animals generally took smaller strides with
DOX reduction over time compared to TDP-43 controls.
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Interestingly, there was a statistically significant interaction
between the TDP-43M337V expression and DOX reduction
time on body speed (n ≥ 6/group, F (3.2, 73) = 2.873,
p = 0.039; Fig. 1h), with no main effect of time (F (3.2, 73) =
1.684, p = 0.175) or genotype (F (1, 23) = 2.712, p = 0.113),
implicating that ChAT-tTA/TRE-TDP-43M337V animals
reduced their speed with DOX reduction over time, compared to TDP-43 controls (see Additional file 3: Figure
S3A-B for other CatWalk results).
Startle box testing revealed no main interactions between genotype or tau and DOX reduction time on
baseline startle or PPI (p > 0.05; Additional file 4: Figure
S4A-D). While ANOVA detected a main effect of genotype on PPI (p = 0.047; Additional file 4: Figure S4C),
this effect cannot be deduced to DOX reduction over
time as ChAT-tTA/TRE-TDP-43M337V rats displayed
generally lower PPI, even at baseline, with no main effect
of time (p > 0.05; see Additional file 4: Figure S4A-D for
ASR results, see also Additional file 8).
The expression of any tau type had no effect on distance travelled or thigmotaxis (Additional file 5: Figure
S5), though there was a significant interaction between
the TDP-43M337V expression on DOX reduction time on
thigmotaxis where ChAT-tTA/TRE-TDP-43M337V rats
generally spent more time in the center of the open field
than the TDP-43 controls (p = 0.022; Additional file 5:
Figure S5C.
There were no significant main effects found for social recognition or sociability testing (p > 0.05; see Additional file 6:
Figure S6A-D for social test results).
Neuroimaging

No differences between groups were observed in either
the corpus callosum or hippocampus by neuroimaging
as measured by ODI, NDI, or IsoVF (Additional file 7:
Figure S7).

Discussion
By using a rat model in which the expression of pathological TDP-43 can be modulated, we have determined
that animals expressing a pathological tau species
(tauT175D) exhibit increased tau pathology in the hippocampus, even when the expression of TDP-43 is in
distant cells. Behaviour and motor tests showed that the
expression of TDP-43 did lead to a predictable and
detectable motor dysfunction as expected. Our studies
have demonstrated that the co-expression of two of the
most common hallmark neuropathological proteins associated with neurodegeneration can behave in a synergistic
manner even when acting at a distance. This exacerbation
was accompanied by markers of neuroinflammation and
apoptosis, suggesting that the dual effect of two pathological proteins produces an increase in systems-level
toxic changes in the central nervous system.
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The exacerbation of tau pathology by a toxic variant of
TDP-43 adds another level of complexity to the role of
tau protein as either a principal or secondary toxic protein in the neurodegenerative process. The induction of
tau protein pathology by cell stressors has been suggested to be a mechanism of tau pathology in traumatic
brain injury and Alzheimer’s disease among others [1].
After induction, tau protein has the capacity to feed forward, generating further tau toxicity. Our experiments
suggest that other toxic proteins associated with neurodegeneration (in this case TDP-43) can exacerbate tau
pathology. While our studies do not allow for a differentiation of a primary tauopathy from a secondary tauopathy as a response to cellular injury, it would be
reasonable to expect that the effect will be the same with
a further induction of the tauopathy. This is of particular
relevance in that tau pathology is frequently observed
alongside other pathogenic protein deposition. While
this current series of experiments has focused on the
development of an in vivo model of ALSci, it is of note
that we have also shown pathogenic phospho-Thr175 tau
protein deposition in a series of neurodegenerative diseases [24]. This concept may be extended to Alzheimer’s
disease, Lewy body dementia, and any neurodegenerative
disease where tau protein may be comorbid with another
proteinopathy [3].
It has been recently reported that tau protein and
TDP-43 can be observed to co-localize within RNA
granules [15]. In this case, tau metabolism may be directly impacted by pathological TDP-43 contributing to
further tau pathology. This potential interaction between
tau and RNA binding proteins has also been supported
by the observation of a more aggressive tau pathology in
a clinical case with both fused in sarcoma (FUS) and tau
pathology [10, 36].
Of particular interest in our study was the observation
that the increase in cortical tauT175D pathology was not
dependant on the co-expression of pathologic tau and
TDP-43 within the same cell populations, suggesting
that an intermediary cell population or factor(s) may
drive these changes. It is noteworthy therefore that we
observed the presence of hippocampal microglial activation in the TDP-43M337V expressing rats. While the
concept that microglial activation can drive a more
prominent tauopathy has been previously suggested, it is
not clear by what mechanism this may occur [38]. Further while a direct effect through cytokine release could
be postulated, we have also observed a trend towards an
increase in spinal motor neuron pathology in ChATtTA/TRE-TDP-43M337V rats expressing rAAV9 constructs in the hippocampus. This occurred in the
absence of obvious corticospinal tract degeneration and
thus it seems unlikely to be related to enhanced transsynaptic degeneration. Rather, in both the cortical and
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spinal motor neuron pathology, synergistic pathology
factors acting both locally and at a distance such as exosomes could be postulated. While spinal fluid was not
collected in this current study, future studies will do so
in order to further clarify the mechanism(s) of pathology
synergism that we have observed.
This study was limited by low numbers as animals
were extremely challenging to generate and carrying
them to the required time point was not easy due to
health challenges encountered by aged animals in this
line [22]. This limited the power of neuroimaging and
behavioural studies to detect differences between groups.
Regardless, age is a challenging component of neurodegenerative disease to model and the adult onset expression of two pathological proteins at advanced age was
critical to the question asked in this study. Surprisingly,
we did not detect any behavioural changes in these rats,
even though the anticipated motor phenotype manifested as expected, and pathology was increased with the
expression of both proteins. However, this was a comparatively short study after the induction of TDP-43
expression, and it is possible that changes were beginning but needed more time to manifest completely. Both
neuroimaging and behavioural analyses may also lack
the sensitivity necessary to detect the subtle changes in
small brain regions as observed in this study. For neuroimaging, the digital masking of the CA2 region of the
hippocampus was not possible due to the small size of
the brain structure, so assessment of this region by
NODDI was not possible. Irrespective of this inability to
detect subtle changes, the observed enhancement effect
of the neuropathology in this model warrants further
investigation.
The DOX used in this model may have introduced a
confounding factor through an unintended neuroprotective effect [29]. This possibility, in the light of the increase in neuropathology, might suggest that our results
have underestimated the impact of the synergistic effect
of expressing two toxic variants of neurodegenerationrelated proteins.
The synergy between two pathological proteins in the
same nervous system may be cause to reconsider the
framework used to classify neurodegenerative disease for
therapeutic intervention. Historically, attempts to connect
different clinical phenotypes with a specific type of protein
inclusion have been made. This has led to increasingly
complex systems of classification which aim to stratify
clinical presentation based on the predominant types of
inclusion (protein composition and morphology) [26].
Our findings would suggest that this framework is inadequate for understanding of the mechanisms underlying
the progressive neuronal death in neurodegenerative disease. Indeed, the presence of comorbid pathologies is increasingly the rule rather than the exception, complicating
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the neuropathological and clinical correlations. We have
also previously suggested that the location of neuronal
death rather than specific protein is likely to be responsible for clinical presentation of disease and that any toxic
protein that may disturb the same population of neurons
will generate the same clinical phenotype [23]. Effective
therapeutic intervention may only be possible when
accounting for the coalescence of pathologies in each individual case, irrespective of clinical presentation.
Our observations are of specific importance to our
understanding of ALS with an accompanying frontotemporal dysfunction. Specifically, the trend towards aninduction of greater spinal motor neuron pathology in
the presence of neocortical tau pathology may provide
an insight into the more rapid disease course observed
in ALS when a frontotemporal dementia phenotype is
present [7, 11, 18]. Importantly, these two clinical manifestations are associated with TDP-43 and tau protein
pathological deposition in the spinal cord and brain, respectively. Therefore, beyond shifting the understanding
of the disease process itself, the finding that the presence
of synergistic neuropathology in the disease process may
shed light on clinical observations that remain unexplained and have important implications for prognosis in
this population. While synergy between proteins has been
described previously (particularly for Alzheimer’s disease
between amyloid-beta and tau [27] and potentially involving prion-proteins as well [27]), our data support the concept that the net effect of expressing two pathogenic
proteins within the nervous system, even if such proteins
are expressed in different cell types, is a synergistic increase in pathology. Given that this model may more fully
reflect the pathology of neurodegeneration in affected
humans, future studies should employ such a model when
examining for therapeutic drug efficacy.

Conclusion
In this series of experiments, we have extended our previous observations to confirm the in vivo pathogenecity of
Thr175Asp tau (tauT175D;a pseudophosphorylated tau
construct mimicking pThr175 tau) and to demonstrate
that the co-expression of mutant TDP-43 (TDP-43M337V)
acts synergistically to significantly increase the neuropathological features of this experimental tauopathy. Critically, this synergism does not require the co-localization
of either pathogenic protein within the same cells and
indeed, there is evidence that the neocortical pathology induced by the tauT175D augments the spinal motor neuron
pathology observed as a consequence of the expression of
TDP-43M337V. While the mechanism by which this synergism occurs remains the subject of ongoing experiments,
these observations have important consequences on our
understanding of the impact of dual pathologies in a broad
range of neurodegenerative disorders.

Moszczynski et al. Acta Neuropathologica Communications

(2019) 7:170

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s40478-019-0816-1.
Additional file 1: Figure S1. Schematic depicting the rat model used
in the TDP-43M337V experiments. A) Cartoon representation of background
(Sprague-Dawley) line used to generate ChAT-tTA (Choline acetyltransferase promoter paired with tetracycline transactivator promoter) and TRETDP-43M337V (tetracycline response element paired with mutant human
TDP-43M337V) non-expressor lines. Crossing these two lines generates the
ChAT-tTA/TRE-TDP-43M337V animals used in experiments. B) Cartoon
representation of TDP-43M337V suppression by tTA in the presence of
doxycycline (DOX) and expression in the absence of doxycyline.
Additional file 2: Figure S2. Astrogliosis is not elevated in the
hippocampus of ChAT-tTA/TRE-TDP-43M337V rats expressing tauT175D. A)
GFAP staining in ChAT-tTA rat hippocampus. B) GFAP staining in tauT175D
expressing hippocampus on the TDP-43 expressing genetic background.
C) Quantification of GFAP positive field of view shows no statistical difference in coverage (proxy for astrocytic activation) in ChAT-tTA/TRE-TDP43M337V rats expressing any GFP construct (GFP = green fluorescent
protein, tauWT = GFP-tagged tauWT; tauT175D = GFP-tagged tauT175D) in the
hippocampus. All quantification represents GFP-tau expressing group on
ChAT-tTA/TRE-TDP-43M337V rats’ transgenic background. Images taken
using 20x objective. Scale bar = 50 μm.
Additional file 3: Figure S3. CatWalk hind paw stride length and body
speed were disrupted in ChAT-tTA/TRE-TDP-43M337V rats upon doxycycline (DOX) reduction over time. A) The interaction between the TDP43M337V and DOX reduction time on hind paw swing; the duration of
time the paw was not in contact with the glass plate was not significant
(n ≥ 6/group, p = 0.178). B) There was no statistically significant interaction between the TDP-43M337V and DOX reduction time on hind paw
swing speed (speed of the paw while taking a step), however we were
approaching significance (n ≥ 6/group, p = 0.059).
Additional file 4: Figure S4. Startle and prepulse inhibition were
unaffected by 50% doxycycline (DOX) reduction. A) Startle box testing
revealed no significant interaction between TDP-43M337V expression and
DOX reduction over time on baseline startle response, (n ≥ 6/group,
p = 0.772). There was no statistically significant difference in mean baseline startle between ChAT-tTA/TRE-TDP-43M337V and TDP-43 controls
(p = 0.364). B) Within ChAT-tTA/TRE-TDP-43M337V rats there was no significant interaction between the tau AAV9 vector injection groups and time
on baseline startle response (p = 0.097). C) No interaction between TDP43M337V and time on PPI (p = 0.868). There was a significant difference in
mean PPI between ChAT-tTA/TRE-TDP-43M337V and TDP-43 controls
(p = 0.047), where ChAT-tTA/TRE-TDP-43M337V animals generally had lower
levels of PPI than the control group, regardless of the time point. *p = 0.047.
D) Within ChAT-tTA/TRE-TDP-43M337V rats there was no significant main
interaction of tau AAV9 vector injection groups and time on PPI (p = 0.607).
The main effect of time showed no statistically significant difference on
mean PPI (p = 0.065). There was no statistically significant difference in mean
PPI between injection groups (p = 0.314). GFP = green fluorescent protein,
tauWT = GFP-tagged tauWT, tauT175D = GFP-tagged human tauT175D.
Additional file 5: Figure S5. Open field testing. A) No significant
interaction was identified by mixed ANOVA between TDP-43M337V and
doxycycline (DOX) reduction over time on cumulative distance traveled,
(n ≥ 5/group, p = 0.161). Similarly, there were no main effects of time
(p = 0.421) or genotype (p = 0.502) on cumulative distance traveled. B)
Within ChAT-tTA/TRE-TDP-43M337V rats, there were no significant main
effects of time (p = 0.824), tau injection groups (p = 0.085), or the interaction between the two on cumulative distance traveled (n ≥ 3/group,
p = 0.300). C) Mixed ANOVA revealed a significant interaction between
TDP-43M337V and DOX reduction over time on thigmotaxis, (n ≥ 4/group,
p = 0.022). The main effect of time also showed a statistically significant
difference in mean thigmotaxis at the different time points, (p = 0.039),
however post hoc t-tests with Bonferroni correction revealed no significant
differences between any of the time points (p ≥ 0.05). There was also a
significant difference in mean thigmotaxis between ChAT-tTA/TRE-TDP43M337V and TDP-43 controls (p = 0.039) regardless of the time, suggesting
that control animal generally spent more time in the perimeter as opposed
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to the centre of the open-field (* p ≤ 0.05). D) Within ChAT-tTA/TRE-TDP43M337V rats, there was no significant interaction between tau and time on
thigmotaxis, (n ≥ 3/group, p = 0.240). Main effect of time showed a statistically significant difference in mean thigmotaxis at the different time points
(p = 0.001) and post hoc t-tests with Bonferroni correction revealed a significant difference between baseline (before DOX reduction) and 2 weeks
following DOX reduction (p = 0.004). There was no statistically significant
difference in mean thigmotaxis between injection groups (p = 0.383). GFP =
green fluorescent protein, WT-tau = GFP-tagged wild-type human tau,
Thr175Asp-tau = GFP-tagged Thr175Asp human tau. *p ≤ 0.05.
Additional file 6: Figure S6. Sociability and social novelty. A) Mixed
ANOVA found no statistically significant interaction between TDP-43M337V
and time on sociability difference score, (n ≥ 3/group, p = 0.413). There
was also no main effect of time (p = 0.426) or genotype (p = 0.473) on
sociability difference score. B) No statistically significant effect of time
(p = 0.757), genotype (p = 0.495), or the interaction between the two on
sociability difference score (n ≥ 2/group, p = 0.102). C) No statistically
significant interaction between TDP-43M337V and time on social preference difference score (n ≥ 2/group, p = 0.101). The main effect of time
showed no statistically significant difference in social preference difference score at the different time points (p = 0.232). There was also no statistically significant difference in mean social preference difference score
between ChAT-tTA/TRE-TDP-43M337V and TDP-43 controls (p = 0.163). D)
No statistically significant interaction between tau AAV9 injection groups
and DOX reduction time on social preference difference score (n ≥ 2/
group, p = 0.535). The main effect of time showed no statistically significant difference in mean social preference difference score at the different
time points (p = 0.296). There was also no statistically significant difference in mean social preference difference score between injection
groups (p = 0.295). GFP = green fluorescent protein, tauWT = GFP-tagged
human tauWT, tauT175D = GFP-tagged human tauT175D.
Additional file 7: Figure S7. Neurite Orientation Dispersion and
Density Imaging (NODDI) diffusion weighted magnetic resonance
imaging (dMRI) in transgenic rats. A) Representative images showing
Orientation Dispersion Index (ODI) Neurite Density Index (NDI), and the
CSF volume fraction (IsoVF). B) No differences were observed between
rAAV9-GFP-tau construct groups in ODI, NDI, or IsoVF in the corpus callosum. C) No differences were observed between GFP-tau construct groups
in ODI, NDI, or IsoVF in the hippocampus. Data represent mean of four
animals per group. GFP = green fluorescent protein, tauWT = GFP-tagged
human tauWT, tauT175D = GFP-tagged human tauT175D.
Additional file 8. Behavioural results.
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